FURIGO, ISADORA C.SUZUKI, MIRIAM F.OLIVEIRA, JOAO E.RAMOS-LOBO, ANGELA M.TEIXEIRA, PRYSCILA D.S.PEDROSO, JOAO A.ALENCAR, AMANDA deZAMPIERI, THAIS T.BUONFIGLIO, DANIELLA C.QUARESMA, PAULA G.F.PRADA, PATRICIA O.BARTOLINI, PAOLOSOARES, CARLOS R.J.DONATO JUNIOR, JOSE2018-12-282018-12-282019FURIGO, ISADORA C.; SUZUKI, MIRIAM F.; OLIVEIRA, JOAO E.; RAMOS-LOBO, ANGELA M.; TEIXEIRA, PRYSCILA D.S.; PEDROSO, JOAO A.; ALENCAR, AMANDA de; ZAMPIERI, THAIS T.; BUONFIGLIO, DANIELLA C.; QUARESMA, PAULA G.F.; PRADA, PATRICIA O.; BARTOLINI, PAOLO; SOARES, CARLOS R.J.; DONATO JUNIOR, JOSE. Suppression of prolactin secretion partially explains the antidiabetic effect of bromocriptine in ob/ob mice. <b>Endocrinology</b>, v. 160, n. 1, p. 193-204, 2019. DOI: <a href="https://dx.doi.org/10.1210/en.2018-00629">10.1210/en.2018-00629</a>. DisponÃvel em: http://repositorio.ipen.br/handle/123456789/29404.0013-7227http://repositorio.ipen.br/handle/123456789/29404Previous studies have shown that bromocriptine mesylate (Bromo) lowers blood glucose levels in adults with type 2 diabetes mellitus; however, the mechanism of action of the antidiabetic effects of Bromo is unclear. As a dopamine receptor agonist, Bromo can alter brain dopamine activity affecting glucose control, but it also suppresses prolactin (Prl) secretion, and Prl levels modulate glucose homeostasis. Thus, the objective of the current study was to investigate whether Bromo improves insulin sensitivity via inhibition of Prl secretion. Male and female ob/ob animals (a mouse model of obesity and insulin resistance) were treated with Bromo and/or Prl. Bromo-treated ob/ob mice exhibited lower serum Prl concentration, improved glucose and insulin tolerance, and increased insulin sensitivity in the liver and skeletal muscle compared with vehicle-treated mice. Prl replacement in Bromo-treated mice normalized serum Prl concentration without inducing hyperprolactinemia. Importantly, Prl replacement partially reversed the improvements in glucose homeostasis caused by Bromo treatment. The effects of the Prl receptor antagonist G129R-hPrl on glucose homeostasis were also investigated. We found that central G129R-hPrl infusion increased insulin tolerance of male ob/ob mice. In summary, our findings indicate that part of Bromo effects on glucose homeostasis are associated with decrease in serum Prl levels. Because G129R-hPrl treatment also improved the insulin sensitivity of ob/ob mice, pharmacological compounds that inhibit Prl signaling may represent a promising therapeutic approach to control blood glucose levels in individuals with insulin resistance.193-204openAccessendocrine diseasesbromineglucoseinsulindiabetes mellitushomeostasismiceSuppression of prolactin secretion partially explains the antidiabetic effect of bromocriptine in ob/ob miceArtigo de periódico116010.1210/en.2018-00629aguardandohttps://orcid.org/0000-0002-7982-178972.37883.00